Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

OBJECTIVES: To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA). METHODS: Patients (2–19 years) entered two phase III studies and continued in the long-term extension (LTE) study. Efficacy assessments were performed every...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruperto, Nicolino, Brunner, Hermine I, Quartier, Pierre, Constantin, Tamàs, Wulffraat, Nico M, Horneff, Gerd, Kasapcopur, Ozgur, Schneider, Rayfel, Anton, Jordi, Barash, Judith, Berner, Reinhard, Corona, Fabrizia, Cuttica, Ruben, Fouillet-desjonqueres, Marine, Fischbach, Michel, Foster, Helen E, Foell, Dirk, Radominski, Sebastião C, Ramanan, Athimalaipet V, Trauzeddel, Ralf, Unsal, Erbil, Levy, Jérémy, Vritzali, Eleni, Martini, Alberto, Lovell, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241618/
https://www.ncbi.nlm.nih.gov/pubmed/30269054
http://dx.doi.org/10.1136/annrheumdis-2018-213150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241618/
https://www.ncbi.nlm.nih.gov/pubmed/30269054
http://dx.doi.org/10.1136/annrheumdis-2018-213150

Ejemplares similares